Erasmus MC Safety Committee approves Phase 2 study of Ampligen + Imfinzi for late-stage pancreatic cancer

AIM ImmunoTech Inc.

Phase 1 safety data showed combination generally well-tolerated with no severe adverse events or dose-limiting toxicities.
Phase 1 safety data showed combination generally well-tolerated with no severe adverse events or dose-limiting toxicities.
CEO Tom Equels and Prof. van Eijck discussed milestone in Virtual Investor segment.
Study is investigator-initiated, single-center at Erasmus MC in the Netherlands.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.